Petros Pharmaceuticals announces deconsolidation of Metuchen subsidiary

Petros Pharmaceuticals (PTPI) announces the strategic deconsolidation of its wholly owned subsidiary, Metuchen Pharmaceuticals, including its wholly owned subsidiaries, Timm Medical Technologies, Inc. and Pos-T-Vac, from its consolidated balance sheet, effective beginning in its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025. This move is expected to significantly improve Petros’ financial position, increasing stockholders’ equity and materially reducing consolidated debt. The deconsolidation of Metuchen is part of a broader corporate realignment strategy aimed at streamlining operations and enhancing financial flexibility. Following the deconsolidation, Petros anticipates a strengthened balance sheet that will enable the company to meet the minimum stockholders’ equity requirement for listing on the Nasdaq Capital Market. Petros is currently in the process of appealing Nasdaq’s recent decision to delist its common stock. The Company believes that the deconsolidation, coupled with other internal initiatives, demonstrates substantial progress toward regaining compliance.